Alliance Pharma plc

AIM:APH Stock Report

Market Cap: UK£239.7m

Alliance Pharma Past Earnings Performance

Past criteria checks 0/6

Alliance Pharma's earnings have been declining at an average annual rate of -67.2%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 7.8% per year.

Key information

-67.2%

Earnings growth rate

-67.3%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate7.8%
Return on equity-15.1%
Net Margin-18.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Sep 10
Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Is Alliance Pharma (LON:APH) A Risky Investment?

Jun 21
Is Alliance Pharma (LON:APH) A Risky Investment?

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Feb 23
Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Nov 21
Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

May 26
We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Mar 24
Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Sep 30
We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

May 28
An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Mar 30
Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Dec 24
Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Nov 19
Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Revenue & Expenses Breakdown

How Alliance Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

AIM:APH Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24183-34560
31 Mar 24182-33550
31 Dec 23181-33530
30 Sep 23175-31590
30 Jun 23170-29640
31 Mar 23169-25640
31 Dec 22167-21640
30 Sep 22165-5630
30 Jun 2216312620
31 Mar 2216310620
31 Dec 211637620
30 Sep 2115513590
30 Jun 2114718550
31 Mar 2113813500
31 Dec 201308460
30 Sep 2013110460
30 Jun 2013111460
31 Mar 2013318470
31 Dec 1913625480
30 Sep 1913323480
30 Jun 1913021480
31 Mar 1912420460
31 Dec 1811818440
30 Sep 1811221400
30 Jun 1810724360
31 Mar 1810427350
31 Dec 1710229330
30 Sep 1710125330
30 Jun 1710022320
31 Mar 179920310
31 Dec 169718300
30 Sep 168518260
30 Jun 167218220
31 Mar 166015190
31 Dec 154813160
30 Sep 154711160
30 Jun 15458150
31 Mar 15448140
31 Dec 14448130
30 Sep 14448130
30 Jun 14449130
31 Mar 14459130

Quality Earnings: APH is currently unprofitable.

Growing Profit Margin: APH is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APH is unprofitable, and losses have increased over the past 5 years at a rate of 67.2% per year.

Accelerating Growth: Unable to compare APH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).

Return on Equity

High ROE: APH has a negative Return on Equity (-15.07%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:22
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alliance Pharma plc is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Julie SimmondsCanaccord Genuity
Mark BrewerCavendish